TheraRadar
Clinical-Stage Companies / Sichuan Haisco Pharmaceutical Group

Sichuan Haisco Pharmaceutical Group

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 11/15/2020

30
Total Trials
5
Phase 3
5
Phase 2
0
Recruiting
172
Score

Pipeline by Phase

Phase 3
5
Phase 2
5
Phase 1
19

Therapeutic Focus

Sedation Anesthesia Healthy Diabetes Mellitus, Type 2 Sedation or Anesthesia

Clinical Trials (30)

NCT04556851 Phase 3 COMPLETED

HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Started: 9/29/2020

NCT04564872 Phase 3 COMPLETED

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Started: 11/13/2020

NCT04111159 Phase 3 COMPLETED

A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy

Started: 12/6/2019

NCT03808844 Phase 3 COMPLETED

A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion for the Induction of General Anesthesia in Elective Surgery Subjects

Started: 3/22/2019

NCT03674008 Phase 3 COMPLETED

A Phase III Study Evaluating The Efficacy and Safety of HSK3486 for Sedation or Anesthesia

Started: 10/9/2018

NCT04147416 Phase 2 COMPLETED

A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

Started: 11/22/2019

NCT04048811 Phase 2 COMPLETED

A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients

Started: 12/9/2019

NCT03773042 Phase 2 COMPLETED

A Study Evaluating Tolerability, Efficacy, and Safety of HSK3486 Injectable Emulsion in Patients

Started: 12/1/2016

NCT03709056 Phase 2 COMPLETED

A Study Evaluating the Efficacy and Safety of HSK3486

Started: 12/14/2017

NCT03698617 Phase 2 COMPLETED

A Phase IIa Study Investigating the Tolerance, Efficacy and Safety of HSK3486

Started: 12/6/2016

NCT04213196 Phase 1 COMPLETED

Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

Started: 1/9/2020

NCT04540016 Phase 1 COMPLETED

Mass Balance and Biotransformation of [14C]HSK7653 in Human

Started: 11/15/2020

NCT03751969 Phase 1 WITHDRAWN

A Study Evaluating the Mass Balance of Micro-dose[14C]HSK3486 Emulsion Injection in Healthy Adults

Started: 3/30/2020

NCT04110886 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers

Started: 7/2/2020

NCT04526496 Phase 1 COMPLETED

Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers

Started: 2/24/2020

NCT04029766 Phase 1 COMPLETED

A Study Evaluating Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of HSK3486 Single Bolus Dose Followed With a 30 Minute Constant Infusion in Healthy Male Subjects

Started: 11/10/2015

NCT04142970 Phase 1 COMPLETED

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

Started: 1/5/2020

NCT04145583 Phase 1 COMPLETED

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets

Started: 12/14/2019

NCT04197661 Phase 1 COMPLETED

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Started: 12/25/2019

NCT04145596 Phase 1 COMPLETED

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment

Started: 11/14/2019

NCT04556058 Phase 1 COMPLETED

A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on an Empty Stomach in Healthy Subjects

Started: 11/29/2018

NCT04556110 Phase 1 COMPLETED

A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on After Meals in Healthy Subjects

Started: 11/20/2018

NCT03773835 Phase 1 COMPLETED

A Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.

Started: 5/1/2016

NCT03745625 Phase 1 COMPLETED

A Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486

Started: 1/9/2019

NCT03751956 Phase 1 COMPLETED

A Study Evaluating the Mass Balance of [14C]HSK3486 Emulsion Injection in Healthy Adults.

Started: 1/6/2019

NCT03758469 Phase 1 COMPLETED

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules

Started: 12/14/2018

NCT04054063 Phase 1 COMPLETED

A Study Evaluating Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 and Etomidate for Induction of Anesthesia in Healthy Male Subjects

Started: 11/30/2016

NCT04037657 Phase 1 COMPLETED

Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Female Subjects.

Started: 4/22/2015

NCT04033939 Phase 1 COMPLETED

A Study Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Subjects.

Started: 4/13/2014

NCT04595916 Phase 4 COMPLETED

Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury

Started: 4/4/2020

Drug Candidates

HSK21542 [14C]HSK7653 HSK7653 10 mg Q2W HSK7653 25 mg Q2W Placebo Linagliptin 5 mg QD HSK3486 HSK3486 0.1-0.2 /0.3 mg / kg group Propofol 0.5-1.0/1.5 mg/kg group FTP-198, single dose
Activity Status: Inactive
Last Trial Started: 11/15/2020
Last Trial Ended: 8/29/2022
Trials (12 months): 0
Completed Trials: 29
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.